# Evaluation of Imaging Characteristics of [18F]PI-2620 PET in AD and PSP Patients Using High and Low Specific Activity

> **NCT04715750** · PHASE1 · COMPLETED · sponsor: **Life Molecular Imaging GmbH** · enrollment: 10 (actual)

## Conditions studied

- Alzheimer Disease
- Progressive Supranuclear Palsy

## Interventions

- **DRUG:** [18F]-PI2620

## Key facts

- **NCT ID:** NCT04715750
- **Lead sponsor:** Life Molecular Imaging GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-12
- **Primary completion:** 2022-10-26
- **Final completion:** 2022-10-26
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2025-05-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04715750

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04715750, "Evaluation of Imaging Characteristics of [18F]PI-2620 PET in AD and PSP Patients Using High and Low Specific Activity". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT04715750. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*